EDUCATION > Educational Programs > E-Learning > Videos/Webcasts > 2013 Annual Meeting Webcasts > Prostate Cancer > Module 6: Sequencing Novel Agents in Advanced Prostate Cancer 2013: Case-Based Key Knowledge for Urologists

Module 6: Sequencing Novel Agents in Advanced Prostate Cancer 2013: Case-Based Key Knowledge for Urologists

Introduction/Activity Overview Statement of Need

This course will include short didactic lectures followed by case presentations to give participants an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed.

Learning Objectives

After participating in this activity, participants should be able to:

  • diagnose castrate resistant prostate cancer and have a working knowledge of treatments and the proper order for administration
  • manage castrate resistant prostate cancer with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy
  • analyze the mechanism of action and risks/benefits of using systemic agents in the treatment of castrate resistant prostate cancer
  • describe the bone-targeted, radiopharmaceutical agent, RADIUM-223 and its sequencing
  • review the new generation antiandrogen agent, Enzalutamide and its sequencing

Faculty/Authors Disclosures

Judd W. Moul, MD, FACS, Director
James H Semans Professor of Surgery
Duke Health System-Urology Division
Durham, NC

P. George Febbo, MD, Faculty
Professor of Medicine and Urology
University of California, San Francisco
San Francisco, CA

J. Kellogg Parsons, MD, Faculty
Associate Professor of Surgery
Moores UC San Diego Comprehensive Cancer Center
La Jolla, CA

Name

Company

Relationship

Financial

P. George Febbo, MD Janssen Meeting Participant or Lecturer Yes
       
Judd W. Moul, MD, FACS Astra Zeneca Scientific Study or Trial Yes
       
J. Kellogg Parsons, MD AMS Meeting Participant or Lecturer Yes
       

Acknowledgement for Support

Support provided by educational grants from the following companies:

Abbvir Algeta AMGEN Astellas
Bayer Janseen Medivation Millennium

Judd W. Moul, MD, FACS
Sequencing Novel Agents in Advanced Prostate Cancer 2013: Case-Based Key Knowledge for Urologists


P. George Febbo, MD
Sequencing Emerging Agents in Castration Resistant Prostate Cancer


J. Kellogg Parsons, MD
Novel Agents for Androgen Deprivation


Questions

ADVERTISEMENT

ADVERTISEMENT
Donate
Contact
Press/Media
Sections
Term of Use
Site Map


ADVERTISEMENT